Selected research
Industry Research
Budesonide (BUD) Industry Research Report 2026
Market perspective
The global Budesonide (BUD) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Budesonide (BUD) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Budesonide (BUD) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Budesonide (BUD) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Budesonide (BUD) include Chiesi Farmaceutici, Cipla, Cosmo Pharmaceuticals, Dr. Falk Pharma, Lunan Better Pharmaceutical, Orion, Shanghai Sine Promod Pharmaceutical, Synmosa Biopharma and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Budesonide (BUD) market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Budesonide (BUD) Market by Company
Chiesi Farmaceutici
Cipla
Cosmo Pharmaceuticals
Dr. Falk Pharma
Lunan Better Pharmaceutical
Orion
Shanghai Sine Promod Pharmaceutical
Synmosa Biopharma
AstraZeneca
Mylan
Sandoz
Teva
Budesonide (BUD) Segment by Type
Pill
Inhaler
Nasal Spray
Budesonide (BUD) Segment by Application
Nose Disease Treatment
Respiratory Disease Treatment
Inflammatory Bowel Disease Treatment
Budesonide (BUD) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Budesonide (BUD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Budesonide (BUD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Budesonide (BUD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Budesonide (BUD) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Budesonide (BUD) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Budesonide (BUD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pill
- Inhaler
- Nasal Spray
Applications
- Nose Disease Treatment
- Respiratory Disease Treatment
- Inflammatory Bowel Disease Treatment
Companies covered
- Chiesi Farmaceutici
- Cipla
- Cosmo Pharmaceuticals
- Dr. Falk Pharma
- Lunan Better Pharmaceutical
- Orion
- Shanghai Sine Promod Pharmaceutical
- Synmosa Biopharma
- AstraZeneca
- Mylan
- Sandoz
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Budesonide (BUD) Market Size (2021-2032)
- 2.2.2 Global Budesonide (BUD) Sales (2021-2032)
- 2.2.3 Global Budesonide (BUD) Market Average Price (2021-2032)
- 2.3 Budesonide (BUD) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pill
- 2.3.3 Inhaler
- 2.3.4 Nasal Spray
- 2.4 Budesonide (BUD) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Nose Disease Treatment
- 2.4.3 Respiratory Disease Treatment
- 2.4.4 Inflammatory Bowel Disease Treatment
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Budesonide (BUD) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Budesonide (BUD) Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Budesonide (BUD) Revenue of Manufacturers (2021-2026)
- 3.4 Global Budesonide (BUD) Average Price by Manufacturers (2021-2026)
- 3.5 Global Budesonide (BUD) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Budesonide (BUD), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Budesonide (BUD), Product Type & Application
- 3.8 Global Manufacturers of Budesonide (BUD), Established Date
- 3.9 Global Budesonide (BUD) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chiesi Farmaceutici
- 4.1.1 Chiesi Farmaceutici Company Information
- 4.1.2 Chiesi Farmaceutici Business Overview
- 4.1.3 Chiesi Farmaceutici Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chiesi Farmaceutici Budesonide (BUD) Product Portfolio
- 4.1.5 Chiesi Farmaceutici Recent Developments
- 4.2 Cipla
- 4.2.1 Cipla Company Information
- 4.2.2 Cipla Business Overview
- 4.2.3 Cipla Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Cipla Budesonide (BUD) Product Portfolio
- 4.2.5 Cipla Recent Developments
- 4.3 Cosmo Pharmaceuticals
- 4.3.1 Cosmo Pharmaceuticals Company Information
- 4.3.2 Cosmo Pharmaceuticals Business Overview
- 4.3.3 Cosmo Pharmaceuticals Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cosmo Pharmaceuticals Budesonide (BUD) Product Portfolio
- 4.3.5 Cosmo Pharmaceuticals Recent Developments
- 4.4 Dr. Falk Pharma
- 4.4.1 Dr. Falk Pharma Company Information
- 4.4.2 Dr. Falk Pharma Business Overview
- 4.4.3 Dr. Falk Pharma Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dr. Falk Pharma Budesonide (BUD) Product Portfolio
- 4.4.5 Dr. Falk Pharma Recent Developments
- 4.5 Lunan Better Pharmaceutical
- 4.5.1 Lunan Better Pharmaceutical Company Information
- 4.5.2 Lunan Better Pharmaceutical Business Overview
- 4.5.3 Lunan Better Pharmaceutical Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lunan Better Pharmaceutical Budesonide (BUD) Product Portfolio
- 4.5.5 Lunan Better Pharmaceutical Recent Developments
- 4.6 Orion
- 4.6.1 Orion Company Information
- 4.6.2 Orion Business Overview
- 4.6.3 Orion Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Orion Budesonide (BUD) Product Portfolio
- 4.6.5 Orion Recent Developments
- 4.7 Shanghai Sine Promod Pharmaceutical
- 4.7.1 Shanghai Sine Promod Pharmaceutical Company Information
- 4.7.2 Shanghai Sine Promod Pharmaceutical Business Overview
- 4.7.3 Shanghai Sine Promod Pharmaceutical Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Shanghai Sine Promod Pharmaceutical Budesonide (BUD) Product Portfolio
- 4.7.5 Shanghai Sine Promod Pharmaceutical Recent Developments
- 4.8 Synmosa Biopharma
- 4.8.1 Synmosa Biopharma Company Information
- 4.8.2 Synmosa Biopharma Business Overview
- 4.8.3 Synmosa Biopharma Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Synmosa Biopharma Budesonide (BUD) Product Portfolio
- 4.8.5 Synmosa Biopharma Recent Developments
- 4.9 AstraZeneca
- 4.9.1 AstraZeneca Company Information
- 4.9.2 AstraZeneca Business Overview
- 4.9.3 AstraZeneca Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AstraZeneca Budesonide (BUD) Product Portfolio
- 4.9.5 AstraZeneca Recent Developments
- 4.10 Mylan
- 4.10.1 Mylan Company Information
- 4.10.2 Mylan Business Overview
- 4.10.3 Mylan Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mylan Budesonide (BUD) Product Portfolio
- 4.10.5 Mylan Recent Developments
- 4.11 Sandoz
- 4.11.1 Sandoz Company Information
- 4.11.2 Sandoz Business Overview
- 4.11.3 Sandoz Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sandoz Budesonide (BUD) Product Portfolio
- 4.11.5 Sandoz Recent Developments
- 4.12 Teva
- 4.12.1 Teva Company Information
- 4.12.2 Teva Business Overview
- 4.12.3 Teva Budesonide (BUD) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Teva Budesonide (BUD) Product Portfolio
- 4.12.5 Teva Recent Developments
5 Global Budesonide (BUD) Market Scenario by Region
- 5.1 Global Budesonide (BUD) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Budesonide (BUD) Sales by Region: 2021-2032
- 5.2.1 Global Budesonide (BUD) Sales by Region: 2021-2026
- 5.2.2 Global Budesonide (BUD) Sales by Region: 2027-2032
- 5.3 Global Budesonide (BUD) Revenue by Region: 2021-2032
- 5.3.1 Global Budesonide (BUD) Revenue by Region: 2021-2026
- 5.3.2 Global Budesonide (BUD) Revenue by Region: 2027-2032
- 5.4 North America Budesonide (BUD) Market Facts & Figures by Country
- 5.4.1 North America Budesonide (BUD) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Budesonide (BUD) Sales by Country (2021-2032)
- 5.4.3 North America Budesonide (BUD) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Budesonide (BUD) Market Facts & Figures by Country
- 5.5.1 Europe Budesonide (BUD) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Budesonide (BUD) Sales by Country (2021-2032)
- 5.5.3 Europe Budesonide (BUD) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Budesonide (BUD) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Budesonide (BUD) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Budesonide (BUD) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Budesonide (BUD) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Budesonide (BUD) Market Facts & Figures by Country
- 5.7.1 South America Budesonide (BUD) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Budesonide (BUD) Sales by Country (2021-2032)
- 5.7.3 South America Budesonide (BUD) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Budesonide (BUD) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Budesonide (BUD) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Budesonide (BUD) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Budesonide (BUD) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Budesonide (BUD) Sales by Type (2021-2032)
- 6.1.1 Global Budesonide (BUD) Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Budesonide (BUD) Sales Market Share by Type (2021-2032)
- 6.2 Global Budesonide (BUD) Revenue by Type (2021-2032)
- 6.2.1 Global Budesonide (BUD) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Budesonide (BUD) Revenue Market Share by Type (2021-2032)
- 6.3 Global Budesonide (BUD) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Budesonide (BUD) Sales by Application (2021-2032)
- 7.1.1 Global Budesonide (BUD) Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Budesonide (BUD) Sales Market Share by Application (2021-2032)
- 7.2 Global Budesonide (BUD) Revenue by Application (2021-2032)
- 7.2.1 Global Budesonide (BUD) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Budesonide (BUD) Revenue Market Share by Application (2021-2032)
- 7.3 Global Budesonide (BUD) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Budesonide (BUD) Value Chain Analysis
- 8.1.1 Budesonide (BUD) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Budesonide (BUD) Production Mode & Process
- 8.2 Budesonide (BUD) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Budesonide (BUD) Distributors
- 8.2.3 Budesonide (BUD) Customers
9 Global Budesonide (BUD) Analyzing Market Dynamics
- 9.1 Budesonide (BUD) Industry Trends
- 9.2 Budesonide (BUD) Industry Drivers
- 9.3 Budesonide (BUD) Industry Opportunities and Challenges
- 9.4 Budesonide (BUD) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst